About this item:

200 Views | 425 Downloads

Author Notes:

Corresponding Author: Derek J. Hausenloy Phone: +65 66015121, Phone: +65 65166719 Email: derek.hausenloy@duke-nus.edu.sq

HEB is shareholder of CellAegis Inc.

PF is a founder and CEO of Pharmahungary, a group of R&D companies.

GH served as a consultant to Servier.

MO was a consultant for Neurovive Pharmaceuticals. DGD served as consultant to Neurovive Pharmaceuticals.

All other authors have no relevant disclosures.

Subjects:

Research Funding:

DJH was funded by the British Heart Foundation (Grant Number FS/10/039/28270), the Rosetrees Trust, and is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. HEB was funded by the Danish Council for Independent Research (11-108354), the Danish Council for Strategic Research (11-115818), the Novo-Nordisk Foundation and Trygfonden.

PF was funded by the Hungarian Scientific Research Fund (OTKA K 109737 and ANN 107803).

HACF is funded by a Startup Grant of the “Excellence Cluster Cardio-Pulmonary System” (ECCPS) from the German Research Foundation (DFG, Bonn, Germany) and the “Peter und Traudl Engelhorn-Stiftung” (Weilheim, Germany) and in part by the Russian Government Program for competitive growth of Kazan Federal University, Kazan (Russian Federation).

GH was supported by the German Research Foundation (He 1320/18-3 and SFB 1116/B8).

TM was funded by the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research #23591086, #2646113).

MRS was funded by Novo-Nordisk Foundation.

DG-D is supported by the Spanish Institute of Health, Instituto de Salud Carlos III (Grants PIE 13/00027, RETICS-RIC, RD12/0042/0021, and PI14/01431).

RS and PF were funded by the European Foundation for the Study of Diabetes (EFSD) New Horizons Collaborative Research Initiative from the European Association for the Study of Diabetes (EASD) and by the European Cooperation in Science and Technology (COST EU-ROS).

PF was funded by the Hungarian Scientific Research Fund (OTKA K 109737 and ANN 107803).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Cardiac & Cardiovascular Systems
  • Cardiovascular System & Cardiology
  • Ischaemic conditioning
  • Myocardial reperfusion injury
  • Cardioprotection
  • RISK and SAFE pathway
  • Mitochondria
  • MITOCHONDRIAL PERMEABILITY TRANSITION
  • ELEVATION MYOCARDIAL-INFARCTION
  • PERCUTANEOUS CORONARY INTERVENTION
  • RANDOMIZED CONTROLLED-TRIAL
  • GLUCAGON-LIKE PEPTIDE-1
  • ARTERY-BYPASS SURGERY
  • CARDIAC MAGNETIC-RESONANCE
  • CONTROLLED CLINICAL-TRIAL
  • GENERATING FREE-RADICALS
  • PERFUSED RABBIT HEART

Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery

Show all authors Show less authors

Tools:

Journal Title:

Basic Research in Cardiology

Volume:

Volume 111, Number 6

Publisher:

, Pages 70-70

Type of Work:

Article | Final Publisher PDF

Abstract:

To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research.

Copyright information:

© 2016, The Author(s).

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote